The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease ...

Novo Nordisk's flagship diabetes and weight-loss drugs, Ozempic and Wegovy, have come under heightened scrutiny after the ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

Don’t be persuaded by the abundance of propaganda you see in ads, newspapers, magazines, TV, and the Internet. There is no ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

An Israeli study found patients taking Ozempic or similar weight-loss shots were twice as likely to suffer from a serious degenerative eye disease compared ... the exact link between weight ...

The European Medicines Agency’s safety committee found that an eye condition called NAION is a “very rare” side effect of semaglutide, a key ingredient in diabetes and obesity drugs. It could affect ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...